EP1529115A2 - Activite de sir2 - Google Patents

Activite de sir2

Info

Publication number
EP1529115A2
EP1529115A2 EP02749837A EP02749837A EP1529115A2 EP 1529115 A2 EP1529115 A2 EP 1529115A2 EP 02749837 A EP02749837 A EP 02749837A EP 02749837 A EP02749837 A EP 02749837A EP 1529115 A2 EP1529115 A2 EP 1529115A2
Authority
EP
European Patent Office
Prior art keywords
sir2
compound
transcription factor
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02749837A
Other languages
German (de)
English (en)
Other versions
EP1529115A4 (fr
Inventor
Leonard Guarente
Homayoun Vaziri
Shin-Ichiro Imai
Wei Gu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Massachusetts Institute of Technology
Original Assignee
Whitehead Institute for Biomedical Research
Massachusetts Institute of Technology
Elixir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Elixir Pharmaceuticals Inc filed Critical Whitehead Institute for Biomedical Research
Publication of EP1529115A2 publication Critical patent/EP1529115A2/fr
Publication of EP1529115A4 publication Critical patent/EP1529115A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Abstract

L'invention concerne des procédés de criblage de composés modulant des processus cellulaires et organismiques par modification de l'activité de SIR2 et/ou de facteurs de transcription, par exemple, p53 ; notamment, des procédés de criblage de composés modifiant la durée de vie et/ou le métabolisme d'une cellule ou d'un organisme par modulation de l'activité de SIR2 et/ou de facteurs de transcription, par exemple, p53 ; et plus précisément, des procédés de criblage de composés modulant l'activité de Sir2 et/ou de facteurs de transcription, par exemple, p53. Plus précisément, l'invention concerne un procédé de criblage d'un composé consistant à utiliser un mélange d'essai renfermant un facteur de transcription de Sir2 et un cofacteur de Sir2 avec le composé, ainsi qu'à évaluer une activité d'un composant du mélange d'essai en présence du composé. L'invention concerne également des utilisations thérapeutiques desdits composés. L'invention concerne enfin un procédé de modification du statut d'acétylation d'un site de liaison de facteur de transcription sur une histone ou un ADN par élévation des concentrations locales de Sir2.
EP02749837A 2001-07-06 2002-07-08 Activite de sir2 Withdrawn EP1529115A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US190159 1988-05-04
US30337001P 2001-07-06 2001-07-06
US30345601P 2001-07-06 2001-07-06
US303370P 2001-07-06
US303456P 2001-07-06
US19015902A 2002-07-05 2002-07-05
PCT/US2002/021461 WO2003004621A2 (fr) 2001-07-06 2002-07-08 Activite de sir2

Publications (2)

Publication Number Publication Date
EP1529115A2 true EP1529115A2 (fr) 2005-05-11
EP1529115A4 EP1529115A4 (fr) 2005-08-24

Family

ID=32074257

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02749837A Withdrawn EP1529115A4 (fr) 2001-07-06 2002-07-08 Activite de sir2

Country Status (4)

Country Link
EP (1) EP1529115A4 (fr)
AU (1) AU2002320325B2 (fr)
CA (1) CA2453195A1 (fr)
WO (1) WO2003004621A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452664B2 (en) 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
US8642284B1 (en) 1999-12-15 2014-02-04 Massachusetts Institute Of Technology Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
US7572575B2 (en) 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
AU2002362030A1 (en) 2001-11-27 2003-06-10 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
AU2003237248A1 (en) 2002-05-23 2003-12-12 The Regents Of The University Of California Methods of modulating mitochondrial nad-dependent deacetylase
US20070099830A1 (en) 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
US8518635B2 (en) 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUARENTE, LEONARD: "SIR2 and aging - the exception that proves the rule", TRENDS IN GENETICS, vol. 17, no. 7, 1 July 2001 (2001-07-01), pages 301-392, *
MUTH VIOLA ET AL: "Acetylation of TAFI68, a subunit of TIF-IB/SL1, activates RNA polymerase I transcription" EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 20, no. 6, 15 March 2001 (2001-03-15), pages 1353-1362, XP002334003 ISSN: 0261-4189 *
See also references of WO03004621A2 *

Also Published As

Publication number Publication date
AU2002320325B2 (en) 2008-04-03
WO2003004621A3 (fr) 2005-03-17
WO2003004621A2 (fr) 2003-01-16
AU2002320325A2 (en) 2003-01-21
EP1529115A4 (fr) 2005-08-24
CA2453195A1 (fr) 2003-01-16

Similar Documents

Publication Publication Date Title
US8546074B2 (en) Sir2 activity
US20040005574A1 (en) SIR2 activity
Olsson et al. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?
Li et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex
Tran et al. Trabid, a new positive regulator of Wnt-induced transcription with preference for binding and cleaving K63-linked ubiquitin chains
US20050136429A1 (en) SIRT1 modulation of adipogenesis and adipose function
JP2008529502A (ja) 細胞及び生物の寿命を延ばし、ストレス耐性を高めるための方法及び組成物
US20060063187A1 (en) Modulation of XBP-1 activity for treatment of metabolic disorders
Davé et al. Nuclear factor of activated T cells regulates transcription of the surfactant protein D gene (Sftpd) via direct interaction with thyroid transcription factor-1 in lung epithelial cells
US20040101879A1 (en) Srebp pathway modulation through targeting hisrs
Xie et al. The proteasome activator REGγ accelerates cardiac hypertrophy by declining PP2Acα–SOD2 pathway
JP2004524021A (ja) ＨｉｓＲＳをターゲッティングすることによるＳＲＥＢＰ経路の調節
Mercy et al. Mitochondrial biogenesis in mtDNA‐depleted cells involves a Ca2+‐dependent pathway and a reduced mitochondrial protein import
US7771961B2 (en) Cytochrome c acetylation
AU2002320325B2 (en) SIR2 activity
AU2002320325A1 (en) SIR2 activity
Ghosh et al. Fibroblasts derived from patients with opsismodysplasia display SHIP2‐specific cell migration and adhesion defects
Homayouni et al. Interaction of Disabled-1 and the GTPase activating protein Dab2IP in mouse brain
Wu et al. CD45 recruits adapter protein DOK-1 and negatively regulates JAK–STAT signaling in hematopoietic cells
WO2003040409A9 (fr) Nouvelles proteines a activite kinase de centre germinatif, compositions et techniques d'utilisation
Li et al. Protein kinase X (PRKX) can rescue the effects of polycystic kidney disease-1 gene (PKD1) deficiency
CA2519161A1 (fr) Activite de sir2
US6887675B1 (en) Tankyrase H, compositions involved in the cell cycle and methods of use
US20050074825A1 (en) Tankyrase H, compositions involved in the cell cycle and methods of use
US20150219630A1 (en) Method for determining activators of excitatory synapse formation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040206

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050712

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

RIN1 Information on inventor provided before grant (corrected)

Inventor name: IMAI, SHIN-ICHIRO

Inventor name: VAZIRI, HOMAYOUN

Inventor name: GUARENTE, LEONARD

17Q First examination report despatched

Effective date: 20080821

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131015